In the News

Ixazomib (Ninlaro) has been approved for use in combination with lenalidomide (Revlimid) and dexamethasone for the treatment of patients with multiple myeloma who have received at least 1 previous therapy. This is the first oral proteasome inhibitor to be approved for this patient population.
Daratumumab (Darzalex) received accelerated approval for patients with multiple myeloma who have received ≥3 treatments, according to the FDA. This is the first monoclonal antibody approved for multiple myeloma.
Today, the US Food and Drug Administration (FDA) granted accelerated approval for an oral medication to treat patients with advanced non—small-cell lung cancer (NSCLC).
The US Food and Drug Administration (FDA) today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can't be removed by surgery, and that has a certain type of abnormal gene.
The US Food and Drug Administration (FDA) today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.
On October 5, the US Food and Drug Administration (FDA) approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia

Healthcare provider (HCP) and payer viewpoints can be very different regarding the treatment and management of patients with chronic conditions. The HCP’s principal responsibility is to the individual, ensuring that every patient under his or her care receives the appropriate treatment necessary to optimize their patients’ health and quality of life. Although the well-being of individual patients remains the major focus, in recent years, HCPs have been forced to view healthcare delivery in a broader context, one that includes the financing side of the equation.

Multiple sclerosis (MS) is a progressive neuroimmunologic disease of the central nervous system, characterized by multiple areas of demyelination, myelin damage and scarring, loss of oligodendrocytes, and axonal and neuronal injury to the white matter of the brain and spinal cord.1 MS is a leading cause of medical neurologic disability in younger people affecting individuals in the prime of their lives, with age of diagnosis between 20 and 50 years of age.2 MS is at least two to three times more common in women than in men.2

As drug costs continue to outpace overall healthcare spending, private health insurers are seeking innovative ways to manage pharmacy utilization. In keeping with this trend, pharmacy management of specialty categories such as multiple sclerosis (MS) has begun to change in recent years.

Through a structured, interactive approach designed to facilitate collaborative discussion, the MS roundtable sought to identify areas of common ground between healthcare providers (HCPs) and payers in making clinically appropriate, value-based patient management decisions. HCPs and payers represented on the panel discussed their responsibilities, goals, and challenges in an open forum that encouraged the candid exchange of ideas.

Page 4 of 5
Results 31 - 40 of 41
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME